Trial Profile
Study of safety and efficacy of long acting pasireotide in patients with active acromegaly
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Apr 2019
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Acromegaly
- Focus Adverse reactions; Therapeutic Use
- 24 Apr 2018 New trial record
- 20 Mar 2018 Results (n=31) presented at The 100th Annual Meeting of the Endocrine Society